Robertson JF, Evans A, Henschen S, Kirwan CC, et al. A randomized, window of opportunity study comparing the effects of the novel oral SERD AZD9496 with fulvestrant in patients with ER+ HER2- primary breast cancer. Clin Cancer Res 2020 Mar 31. pii: 1078-0432.CCR-19-3387.
PMID: 32234755